Aerogen involved in cutting edge project focused on improving the treatment of antibiotic-resistant pneumonia.
The FAIR project has formally began following the team’s first meeting in Paris, France on the 13-14 January, 2020.
The FAIR project will focus on improving the treatment of antibiotic-resistant pneumonia. This has the potential to provide huge benefits on a worldwide scale.
It will receive a total of €10 million in funding from EU Horizon 2020 grants over five years, beginning in January 2020 until December 2024.
Ronan MacLoughlin is the lead from Aerogen on this project.